2. Academic Validation
  3. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease

  • Signal Transduct Target Ther. 2021 May 29;6(1):212. doi: 10.1038/s41392-021-00628-x.
Qi Sun  # 1,  Fei Ye  # 2,  Hao Liang  # 1,  Hongbo Liu  # 1,  Chunmei Li 3,  Roujian Lu 2,  Baoying Huang 2,  Li Zhao 2,  Wenjie Tan 4,  Luhua Lai 5 6
Affiliations

Affiliations

  • 1 BNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing, China.
  • 2 NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China.
  • 3 Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.
  • 4 NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, China CDC, Beijing, China. tanwj28@163.com.
  • 5 BNLMS, Peking-Tsinghua Center for Life Sciences at College of Chemistry and Molecular Engineering, Peking University, Beijing, China. lhlai@pku.edu.cn.
  • 6 Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. lhlai@pku.edu.cn.
  • # Contributed equally.
PMID: 34052830 DOI: 10.1038/s41392-021-00628-x
Figures
Products